Delayed
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
3.75
HKD
|
0.00%
|
|
+1.63%
|
+11.94%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
1,195
|
818
|
786.2
|
827.6
|
951.8
|
1,247
|
Enterprise Value (EV)
1 |
670.3
|
279.8
|
305
|
274.5
|
383.9
|
594.2
|
P/E ratio
|
19.5
x
|
8
x
|
4.69
x
|
5.37
x
|
5.07
x
|
4.43
x
|
Yield
|
6.18%
|
9.53%
|
10.1%
|
4.51%
|
11.4%
|
18.9%
|
Capitalization / Revenue
|
1.91
x
|
1.18
x
|
0.99
x
|
1.28
x
|
1.16
x
|
1.26
x
|
EV / Revenue
|
1.07
x
|
0.4
x
|
0.38
x
|
0.42
x
|
0.47
x
|
0.6
x
|
EV / EBITDA
|
8.44
x
|
1.7
x
|
1.4
x
|
1.64
x
|
1.56
x
|
1.49
x
|
EV / FCF
|
-18
x
|
-50.2
x
|
9.74
x
|
3.43
x
|
-13.6
x
|
4.79
x
|
FCF Yield
|
-5.54%
|
-1.99%
|
10.3%
|
29.1%
|
-7.33%
|
20.9%
|
Price to Book
|
1.26
x
|
0.77
x
|
0.68
x
|
0.68
x
|
0.7
x
|
0.81
x
|
Nbr of stocks (in thousands)
|
739,302
|
739,302
|
739,302
|
739,302
|
739,302
|
739,302
|
Reference price
2 |
1.616
|
1.106
|
1.063
|
1.119
|
1.287
|
1.687
|
Announcement Date
|
4/16/18
|
4/29/19
|
4/24/20
|
4/23/21
|
4/21/22
|
4/26/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
624.1
|
694.2
|
797.1
|
646.9
|
820.5
|
992
|
EBITDA
1 |
79.42
|
164.4
|
218.2
|
167
|
246.1
|
398
|
EBIT
1 |
73.2
|
159.1
|
212.5
|
138.8
|
212.9
|
363.3
|
Operating Margin
|
11.73%
|
22.92%
|
26.65%
|
21.46%
|
25.95%
|
36.62%
|
Earnings before Tax (EBT)
1 |
94.2
|
149.5
|
219.9
|
189.9
|
236.8
|
376
|
Net income
1 |
61.38
|
102.2
|
167.6
|
154.1
|
187.6
|
281.2
|
Net margin
|
9.84%
|
14.72%
|
21.03%
|
23.81%
|
22.87%
|
28.35%
|
EPS
2 |
0.0830
|
0.1382
|
0.2267
|
0.2084
|
0.2538
|
0.3804
|
Free Cash Flow
1 |
-37.16
|
-5.57
|
31.33
|
80.01
|
-28.14
|
124.2
|
FCF margin
|
-5.95%
|
-0.8%
|
3.93%
|
12.37%
|
-3.43%
|
12.52%
|
FCF Conversion (EBITDA)
|
-
|
-
|
14.36%
|
47.92%
|
-
|
31.19%
|
FCF Conversion (Net income)
|
-
|
-
|
18.69%
|
51.94%
|
-
|
44.15%
|
Dividend per Share
2 |
0.0999
|
0.1054
|
0.1073
|
0.0505
|
0.1466
|
0.3184
|
Announcement Date
|
4/16/18
|
4/29/19
|
4/24/20
|
4/23/21
|
4/21/22
|
4/26/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
524
|
538
|
481
|
553
|
568
|
653
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-37.2
|
-5.57
|
31.3
|
80
|
-28.1
|
124
|
ROE (net income / shareholders' equity)
|
6.36%
|
10.2%
|
15.2%
|
13%
|
14.5%
|
19.4%
|
ROA (Net income/ Total Assets)
|
3.27%
|
6.98%
|
8.53%
|
5.24%
|
7.32%
|
10.7%
|
Assets
1 |
1,875
|
1,463
|
1,965
|
2,941
|
2,565
|
2,633
|
Book Value Per Share
2 |
1.280
|
1.430
|
1.560
|
1.650
|
1.850
|
2.080
|
Cash Flow per Share
2 |
0.8300
|
0.8600
|
0.7800
|
0.9500
|
0.9800
|
1.210
|
Capex
1 |
87.6
|
122
|
129
|
83.9
|
48.7
|
15.8
|
Capex / Sales
|
14.04%
|
17.54%
|
16.23%
|
12.98%
|
5.93%
|
1.6%
|
Announcement Date
|
4/16/18
|
4/29/19
|
4/24/20
|
4/23/21
|
4/21/22
|
4/26/23
|
|
1st Jan change
|
Capi.
|
---|
| +11.94% | 354M | | +19.62% | 43.34B | | +20.44% | 21.96B | | +10.86% | 14.09B | | +13.07% | 13.64B | | +37.46% | 11.43B | | -8.59% | 6.86B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +8.46% | 5.22B |
Generic Pharmaceuticals
|